{"classes":[{"categories":[{"measurements":[{"comment":"DoR is a time to event endpoint and because the medians were not met in this study there is no appropriate measure of dispersion of the median","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"22.2"},{"comment":"DoR is a time to event endpoint and because the medians were not met in this study there is no appropriate measure of dispersion of the median","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"16.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"Response is defined as a confirmed best objective response of CR or PR. Duration of response is defined as time from the date of first documented response until date of documented progression or death in the absence of disease progression (provided death is within 3 months of last RECIST assessment). Values are estimated as the medians weren't met","dispersionType":"95% Confidence Interval","groups":[{"description":"Vandetanib (300 mg daily)","id":"OG000","title":"Vandetanib 300 mg"},{"description":"Placebo daily","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"DoR is a time to event endpoint and because the medians were not met in this study there is no appropriate measure of dispersion of the median","reportingStatus":"POSTED","timeFrame":"RECIST tumour assessments were performed at screening (within 3 weeks before date of randomisation), then once every 12 weeks up to and including discontinuation of blinded study treatment, unless patients had withdrawn consent","title":"Duration of Response (DoR)","type":"SECONDARY","unitOfMeasure":"Months"}